8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study is testing a combination of two drugs — 8-chloroadenosine and venetoclax — for people with acute myeloid leukemia (AML, a type of blood cancer) that has returned after treatment or never fully responded to prior treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with AML that has relapsed or is refractory (did not respond to treatment) - You have failed at least one salvage therapy, or you have AML that did not fully respond after two lines of treatment - You are in reasonably good physical condition (ECOG 0–2) and expected to live more than 3 months **You may NOT be eligible if...** - You have AML that has spread to the brain - You have active uncontrolled infections (including HIV, hepatitis B or C) - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding - You are taking medications that strongly interact with the study drugs Talk to your doctor to see if this trial is right for you.